Alice Chen, PhD

Alice Chen, PhD has a diverse work experience spanning over 15 years. Alice is currently the Co-Founder & CSO at Trestle Biotherapeutics, a position they have held since January 2020. Prior to that, they worked at Organovo Holdings, Inc. from May 2015 to October 2019, where they held various roles including Director, Research & Preclinical Development and Director R&D. From July 2013 to April 2015, Alice held the position of Director, Cell Reprogramming at ESI BIO, a division of BioTime, Inc. Alice also worked at Stemgent, Inc. from June 2011 to April 2013, where they served as R&D Manager: Cellular Differentiation; Reprogramming Services and Sr. Scientist, R&D. Alice's early career includes a postdoctoral fellowship at the Harvard Stem Cell Institute from July 2005 to August 2009, where they focused on the use of embryonic stem cells in treating and understanding Type 1 Diabetes. Throughout their career, Alice has made notable contributions to stem cell research, including the derivation of new human ES cell lines and the development of functional assays for testing ES-derived cell types.

Alice Chen, PhD has an extensive educational background in the field of Biology. Alice completed their Bachelor of Arts (BA) in Biology at Pomona College. Afterward, they pursued a PhD in Developmental Biology at The Johns Hopkins University. Alice further enhanced their expertise by participating in a program at Y Combinator in 2021, although the specific degree and field of study are not mentioned. Additionally, they have had some involvement with the field of Biology at UCLA, although no specific degree is specified.